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Abstract: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of
metabolic syndrome. Obesity and unhealthy dietary habits are described as risk factors for NAFLD.
The aim of this study was to investigate the association between the consumption of different animal
protein sources and hepatic status in NAFLD adults. A total of 112 overweight/obese participants
with NAFLD from Fatty Liver in Obesity (FLiO) study were evaluated at baseline. Diet, body
composition, and biochemical variables were evaluated. Hepatic status was also assessed by Magnetic
Resonance Imaging, ultrasonography, and elastography. Red meat consumption showed a positive
relationship with liver iron content (r = 0.224; p = 0.021) and ferritin concentration (r = 0.196; p = 0.037).
Processed meat consumption exhibited a positive association with liver iron content (r = 0.308;
p = 0.001), which was also found in the quantile regression (β = 0.079; p = 0.028). Fish consumption
was related with lower concentration of ferritin (r = −0.200; p = 0.034). This association was further
evidenced in the regression model (β=−0.720; p = 0.033). These findings suggest that the consumption
of different animal protein sources differentially impact on liver status in obese subjects with NAFLD,
showing fish consumption as a healthier alternative for towards NAFLD features.
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1. Introduction
Obesity is a chronic disease, characterized by a low-grade inflammatory systemic manifestation due
to the interaction of multiple factors such as environmental and genetic background among others [1,2].
Obesity rates have increased gradually becoming an important clinical and public health problem. It is
expected that 1.12 billion adults will be obese in the next 10 years [3]. Metabolic comorbidities including
type 2 diabetes, insulin resistance, dyslipidemia, dysbiosis, metabolic syndrome, and non-alcoholic fatty
liver disease (NAFLD) have risen along with the growing incidence of obesity [2,3]. Non-alcoholic fatty
liver disease is considered part of the metabolic syndrome [4,5]. Its prevalence ranges from 6% to
35% in the general population [4]. NAFLD is characterized by an excessive lipid accumulation in the
liver of people who drink little or no alcohol. The most common form of NAFLD is a non-serious
condition called fatty liver. This condition may progress to a more serious state named non-alcoholic
steatohepatitis (NASH), where fat accumulation is associated with liver cell inflammation. NASH is a
potentially severe condition that might lead to liver cirrhosis and patients with cirrhosis may eventually
require a liver transplant [5–8]. Obesity is considered the primary cause of fatty infiltration of the liver;
however, less is known about NASH development. Current investigations tried to identify factors
that may contribute to the development and progression of the disease. Unhealthy Western lifestyle
might play a role in the development and progression of NAFLD, due to the high consumption of
red meat, processed and preserved meat, snacks, refined grains, pastries, sugar-sweetened beverages,
saturated fat, and lack of physical activity [5,9–11]. Global meat consumption has increased over
the past decades and harmful effects have been reported particularly of red and processed meat [9].
Observational studies have shown that red meat consumption seems to be associated with insulin
resistance, type 2 diabetes, metabolic syndrome, and oxidative stress [9,12,13]. In the same way,
processed meat has been related with metabolic syndrome, type 2 diabetes, and high risk of mortality
from all causes [14]. However, data regarding the association between different animal protein sources
and non-alcoholic fatty liver disease are currently lacking or controversial [9,15,16]. In this context, the
aim of this study was to evaluate the relationship between different animal protein sources and hepatic
status in obese patients with NAFLD.
2. Materials and Methods
2.1. Study Participants
The current study included 112 (65 Male and 47 Female) overweight/obese (BMI ≥ 25 to <40 kg/m2)
adults between 40 and 80 years old and with ultrasound-confirmed liver steatosis. The study population
corresponds to patients with NAFLD from the Fatty Liver in Obesity (FLiO) study evaluated at baseline.
The exclusion criteria were defined as presence of known liver disease other than NAFLD, ≥3 kg
body weight loss prior to visit, significant alcohol consumption (>21 standard drinks per week
in men and >14 standard drinks per week in women), endocrine disorders (hyperthyroidism or
uncontrolled hypothyroidism), pharmacological treatments (immunosuppressants, cytotoxic agents,
systemic corticosteroids or the use of steatogenic drugs or medication that alter liver function), existence
of active autoimmune diseases or requiring pharmacological treatment, use of weight-loss medication,
and presence of severe psychiatric disorders. This information was declared by the subjects in the
clinical interview before their enrollment in the study. All study procedures were in accordance with
the Declaration of Helsinki and were approved by the Research Ethics Committee of the University of
Navarra (ref. 54/2015). The study protocol was properly registered in www.clinicaltrails.gov (FLiO:
Fatty Liver in Obesity study; NCT03183193). All participants gave written informed consent.
2.2. Anthropometric, Body Composition, and Biochemical Measurements
Anthropometric measurements were assessed in fasting conditions as described elsewhere [17].
Body weight, waist circumference (WC), body composition (fat mass and lean mass) by dual-energy
X-ray absorptiometry (Lunar iDXA, encore 14.5, Madison, WI, USA), and blood pressure (Intelli Sense.
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M6, OMRON Healthcare, Hoofddorp, The Netherlands) were determined at the Metabolic Unit of
the University of Navarra. Body Mass Index (BMI) was calculated as the body weight divided by the
squared height (kg/m2). Blood samples were properly collected (after 8–10 h of fasting), centrifugated
(15 min; 3500 rpm; 5 ◦C), aliquoted (0.5 mL Eppendorf), and stored at −80 ◦C for further analyses.
Serum glucose, lipid profile parameters: Total cholesterol (TC); high-density lipoprotein cholesterol
(HDL-c); low density lipoprotein cholesterol (LDL-c), and triglycerides (TG) as well as liver enzymes:
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT)
concentrations were determined on an autoanalyzer (Pentra C-200; HORIBA ABX, Madrid, Spain)
following the manufacturer’s instructions. Insulin concentrations were determined using specific
Enzyme-Linked ImmunoSorbent Assay (ELISA) kits (Demeditec; Kiel-Wellsee, Germany) in another
autoanalyzer (Triturus; Grifols, Barcelona, Spain). The homeostatic model assessment of insulin
resistance: HOMA-IR = (insulin (µU/mL) × glucose (mmol/L))/22.5, was used to estimate insulin
resistance. Ferritin serum levels were analyzed by an external certified laboratory (Eurofins Megalab
S.A, Madrid, Spain) using a Chemiluminescent Microparticle Immunoassay (CMIA) technology as
described elsewhere (Abbott Architect Ferritin Assay).
2.3. Lifestyle Assessment: Dietary and Physical Activity
Dietary intake of participants was collected with a semi-quantitative 137-item food frequency
questionnaire (FFQ), validated in Spain [18]. For each item, a typical portion size was included, and
consumption frequencies were registered in nine categories that ranged from “never or almost never”
to “≥6 times/day”. Energy and Nutrient intake was calculated as frequency multiplied by nutrient
composition of specified portion size for each food item, using a computer program based on available
information in Spanish food composition tables [19]. For the purpose of the study, red meat was
defined as meat from mammals without preservation methods: beef, pork, lamb, liver, and viscera [20].
Meat that has been transformed through salting, smoking, or preservation techniques, was defined
as processed meat: bacon, burger, ham, pâté, cold meats, meatballs, and sausages [9]. White meat
included chicken, turkey, rabbit, and hare. Fish was defined as white fish, fatty fish, salted fish, canned
fish, clam, squid and shellfish, and canned shellfish. Physical activity was evaluated using the validated
Spanish version of the Minnesota Leisure-Time Physical Activity Questionnaire [21].
2.4. Liver Status Assessment
Liver status was assessed under fasting conditions by qualified staff at the Clinic University of
Navarra. The presence of hepatic steatosis was determined by means of Ultrasonography (Siemens
ACUSON S2000 and S3000) in accordance with previously described methodology [6]. In addition,
liver stiffness was evaluated by Acoustic Radiation Force Impulse (ARFI) elastography (Siemens
ACUSON S2000 and S3000) and transient elastography through FibroScan® (Echosens, Paris, France).
Ten valid ARFI measurements were performed in each patient [22] to estimate the median value of
liver stiffness. The same qualified radiologist from the department of Ultrasonography and Radiology
executed all the ultrasonographic evaluations. In order to quantify the fat and iron content of the liver
as well as the hepatic volume, a Magnetic Resonance Imaging (MRI) (Siemens Aera 1.5 T) was also
performed to each participant following standardized procedures [6]. The MRI assessment of liver fat
and iron content was performed through the Dixon method.
2.5. Statistical Analyses
Variable distribution was assessed by means of the Shapiro–Wilk test. Data were presented as
mean ± standard deviation. Animal protein variables were categorized according to medians of
consumption (g/day). The cut off points of each animal protein source were the following: red meat
<53.7 g/day and ≥53.7 g/day; processed meat <42.5 g/day and ≥42.5 g/day; white meat <73.05 g/day
and ≥73.05 g/day; fish <88.5 g/day and ≥88.5 g/day. Differences between groups (< and ≥ of the
median) were assessed by the Student’s t-test and the Mann–Whitney U test according to the data
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distribution. The relationship between liver status variables and animal protein consumption was
assessed by the Pearson’s correlation coefficient or the Spearman’s rho (p). Non-parametric variables
were analyzed by quantile regression models and were adjusted for potential confounders such as age,
sex, body mass index, energy intake, and physical activity. Confidence intervals were used to describe
the regression coefficient (β) values. Analyses were performed using 12.0 (Stata Corp, College Station,
TX, USA). All p-values were two-tailed. Values of p < 0.05 were considered statistically significant.
3. Results
The average age of participants was 51± 9 years. Men and women were equally distributed among
medians of protein consumption. No significant differences were observed in animal protein intake
between sexes. Descriptive characteristics of the population according to the median of animal protein
consumption are reported in Table 1. Participants with higher red meat consumption (≥53.7 g/day) had
significantly greater concentrations of triglycerides, alanine aminotransferase, and ferritin (p < 0.05
for all comparisons) than those with lower values of red meat consumption. Subjects with higher
red meat intake showed significantly lower concentrations of HDL-c (p = 0.014) compared to those
with lower consumption. Liver iron content was increased in participants above the median of red
meat consumption compared to those below the median, but no significant differences were observed
(p = 0.067). Variables related to body composition did not show statistical differences between subjects
below and above the median of red meat consumption.
Table 1. Descriptive characteristics of study participants according to the median of animal
protein consumption.
n = 112
Red Meat (g/day) Processed Meat (g/day) White Meat (g/day) Fish (g/day)
<53.7 ≥53.7 <42.5 ≥42.5 <73.05 ≥73.05 <88.5 ≥88.5
Body composition
BMI (kg/m2) 33.9 (4) 33.5 (3) 33.5 (3) 33.9 (4) 34.1 (4) 33.1 (3) 33.2 (4) 34.1 (4)
WC (cm) 110.0 (10) 109.5 (9) 109.8 (10) 109.8 (9) 111.2 (10) 107.9 (9) 108.1 (9) 111.4 (11)
Fat Mass (kg) 40.6 (9) 38.3 (8) 38.6 (7) 40.2 (10) 40.4 (8) 38.2 (9) 38.2 (8) 40.8 (9)
Lean Mass (kg) 51.9 (8) 54.2 (10) 53.0 (10) 53.0 (8) 54.4 (10) 51.3 (9) 52.9 (9) 53.1 (10)
CMRF
Glucose (mg/dL) 110.0 (29) 107.9 (34) 108.0 (26) 109.9 (37) 112.0 (38) 104.9 (14) 109.3 (36) 108.6 (26)
TG (mg/dL) 129.3 (88) 146.3 (70) * 128.7 (75) 146.6 (83) 138.5 (78) 136.8 (82) 141.3 (74) 134.2 (85)
SPB (mmHg) 129.0 (16) 133.5 (12) 131.2 (16) 131.4 (12) 133.5 (15) 128.4 (12) 129.5 (13) 133.1 (15)
DBP (mmHg) 86.3 (11) 87.5 (6) 87.2 (10) 86.1 (7) 87.2 (9) 86.5 (8) 86.3 (8) 87.5 (9)
HDL-c (mg/dL) 54.6 (13) 49.5 (14) * 54.4 (14) 49.8 (14) * 52.3 (14) 51.7 (13) 51.5 (14) 52.6 (14)
LDL-c (mg/dL) 113.9 (31) 121.3 (38) 110.8 (38) 124.1 (31) * 120.2 (32) 114.3 (38) 116.2 (35) 119.1 (35)
TC (mg/dL) 193.6 (36) 200.2 (42) 190.3 (42) 203.3 (36) 199.6 (36) 193.3 (43) 196.1 (38) 197.8 (41)
HOMA-IR 5.5 (4.6) 4.9 (5.0) 5.1 (3.4) 5.3 (5.9) 5.5 (5.3) 4.8 (4.0) 5.2 (5.2) 5.2 (4.4)
HbA1c (%) 5.9 (1.0) 5.8 (1.0) 5.9 (0.9) 5.9 (1.2) 6.1 (1.3) 5.6 (0.3) 5.8 (1.1) 5.9 (1.0)
Insulin (U/mL) 19.2 (13) 17.2 (8) 18.3 (10) 18.2 (12) 18.4 (10) 18.0 (12) 18.1 (10) 18.4 (12)
Liver Status
ALT (IU/L) 29.6 (15) 36.7 (20) * 34.6 (21) 31.7 (14) 34.2 (18) 31.8 (18) 35.7 (19) 30.6 (16)
AST (IU/L) 23.8 (11) 25.1 (8) 25.8 (12) 23.2 (7) 24.8 (10) 23.9 (9) 26.2 (12) 22.7 (7)
GGT (IU/L) 34.9 (24) 40.1 (27) 36.3 (24) 38.7 (27) 36.7 (26) 38.6 (24) 40.4 (27) 34.7 (24)
Ferritin (ng/mL) 119.2 (116) 181.0 (137) * 135.4 (119) 164.3 (139) 144.3 (116) 157.8 (146) 178.7 (147) 121.5 (104)
Liver Fat (%) 9.6 (11.1) 8.7 (7.8) 9.7 (9.6) 8.6 (9.7) 9.6 (10.4) 8.7 (8.6) 8.9 (9.8) 9.4 (9.5)
Liver Iron (%) 34.1 (11) 36.9 (11) 34.1 (12) 37.1 (10) * 36.8 (12) 33.9 (9) 35.6 (11) 35.4 (12)
MRI H.V (mL) 1799 (552) 1855 (444) 1749(461) 1906 (528) 1887 (575) 1752 (376) 1784 (436) 1870 (557)
LSF (kPa) 4.6 (1.8) 5.4 (2.2) 5.5 (2.2) 4.5 (1.8) * 5.2 (2.1) 4.8 (1.9) 4.7 (1.8) 5.3 (2.2)
ARFI (m/s) 1.9 (0.8) 1.7 (0.7) 1.8 (0.7) 1.9 (0.8) 1.8 (0.8) 1.9 (0.7) 1.8 (0.8) 1.8 (0.7)
Steatosis Degree
Grade 1 (n) (%) 30 (53.5%) 32 (57.1%) 27 (49.1%) 35 (61.4%) 34 (53.1%) 28 (58.3%) 30 (53.5%) 32 (57.1%)
Grade 2 (n) (%) 19 (33.9%) 19 (33.9%) 23 (41.8%) 15 (26.3%) 21 (32.8%) 17 (35.4%) 20 (35.7%) 18 (32.1%)
Grade 3 (n) (%) 7 (12.5%) 5 (8.9%) 5 (9.1%) 7 (12.2%) 9 (14.1%) 3 (6.2%) 6 (10.7%) 6 (10.7%)
(Mean ± SD); * p < 0.05; BMI: body mass index; WC: waist circumference; CMRF: cardiometabolic risk factors;
TG: triglycerides; SBP: systolic blood pressure; DPB: diastolic blood pressure; HDL-c: high-density lipoprotein
cholesterol; LDL-c: low-density lipoprotein cholesterol; TC: Total cholesterol; HOMA-IR: homeostatic model
assessment of insulin resistance; HbA1c: glycosylated hemoglobin; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; GGT: gamma-glutamyl transferase; MRI H.V: magnetic resonance imaging hepatic volume; LSF:
liver stiffness; ARFI: acoustic radiation force impulse elastography.
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Significant differences were observed in lipid profile between consumers above and below the
median of processed meat consumption. LDL-c concentration was significantly higher (p = 0.044) while
HDL-c was lower (p = 0.044) in participants with higher processed meat intake (Table 1). Subjects above
the median of processed meat consumption showed greater liver iron content (p = 0.012) and lower liver
stiffness values (p = 0.029). No relevant differences were observed in body composition, cardiometabolic
risk factors, and liver status variables between participants below and above the median of white meat
and fish consumption.
To assess the relationship between different animal protein consumption and hepatic status,
a correlation analysis was applied. No statistical associations were observed between animal protein
consumption and liver fat content: red meat (r = 0.119; p = 0.223), processed meat (r = 0.023; p = 0.815),
white meat (r = −0.040; p = 0.681), and fish intake (r = −0.022; p = 0.822). Red (r = 0.024; p = 0.021) and
processed meat (r = 0.308; p = 0.001) consumption were positively associated with liver iron content
(Figure 1), while no significant associations were observed with white meat (r = −0.029; p = 0.767)
and fish consumption (r = −0.054; p = 0.585). On the other hand, red meat (r = 0.196; p = 0.037)
consumption was associated with ferritin levels, while fish (r = −0.200; p = 0.034) intake showed a
negative relationship (Figure 2). Processed meat (r = 0.108; p = 0.254) and white meat (r = 0.015;
p = 0.869) consumption were not significantly associated to ferritin levels (Figure 2).
A quantile regression analysis was carried out to assess the influence of different animal protein
consumption on hepatic status. Fish consumption showed a negative association with ferritin
concentration (Table 2) (β = −0.720; p = 0.033; 95% CI = −1.383; −0.058). Processed meat consumption
was positively associated with liver iron content (Table 3) (β = 0.079; p = 0.028; 95% CI = 0.028;
0.150), after adjusting by sex, age, body mass index, energy intake (kcal), and physical activity
(METs-min/week).
Figure 1. Correlation analyses to assess the relationship between different animal protein sources
and liver iron content by MRI (%). p < 0.05 was considered statistically significant. MRI: magnetic
resonance imaging.
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Figure 2. Correlations analyses to assess the relationship between different animal protein sources and
ferritin levels. p < 0.05 was considered statistically significant.
Table 2. Quantile regression models with Ferritin as the dependent variable and dietetic factors as
independent variables.
Model 1 Model 2
β (95% CI) p-Value β (95% CI) p-Value
Red Meat 0.349 (−0.271 0.970) 0.267 0.281 (−0.507 1.071) 0.481
Processed Meat 0.230 (−0.762 1.222) 0.647 0.694 (−0.593 1.981) 0.287
White Meat 0.046 (−0.598 0.690) 0.888 −0.208 (−0.917 0.499) 0.560
Fish −0.490 (−1.106 0.126) 0.118 −0.720 (−1.383 −0.058) 0.033
Model 1: adjusted for sex and age; Model 2: adjusted for sex, age, body mass index, energy intake (kcal/day), and
physical activity (METs-min/week).
Table 3. Quantile regression models with Liver Iron Content as the dependent variable and dietetic
factors as independent variables.
Model 1 Model 2
β (95% CI) p-Value β (95% CI) p-Value
Red Meat 0.028 (−0.013 0.070) 0.176 −0.007 (−0.052 0.038) 0.753
Processed Meat 0.048 (−0.020 0.117) 0.162 0.079 (0.008 0.150) 0.028
White Meat 0.002 (−0.034 0.039) 0.882 −0.012 (−0.055 0.030) 0.570
Fish −0.019 (−0.057 0.018) 0.315 −0.017 (−0.059 0.023) 0.395
Model 1: adjusted for sex and age; Model 2: adjusted for sex, age, body mass index, energy intake (kcal/day), and
physical activity (METs-min/week).
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4. Discussion
The present study evaluated the possible association between the consumption of different
animal protein sources with body composition, cardiometabolic risk factors, and hepatic status in
overweight or obese subjects with ultrasonography proven liver steatosis. Red and processed meat
were positively associated with liver iron content and regression analysis showed that processed meat
consumption was involved in the variability of hepatic iron content even after adjustment by potential
confounders. Additionally, red meat showed a positive association with ferritin concentration, while
fish consumption was inversely associated with ferritin levels.
Unhealthy dietary habits are described as risk factors in the development of NAFLD [11].
Poor adherence to healthy dietary patterns and the shift to Western patterns might play an important
role in the development of NAFLD [10,11]. The consumption of foods that characterize Western dietary
patterns such as soft drinks, fructose, red and processed meats, and fast foods have shown to have
detrimental health consequences promoting the development of obesity and associated comorbidities
such as NAFLD [9,23,24]. Concretely meat consumption has steadily increased worldwide, and red and
processed meat represent the majority of meat intake [25]. Meat contains saturated fatty acids (SFA) and
cholesterol which have been described as important risk factors for cardiometabolic diseases, including
NAFLD. More potentially harmful compounds such as heme-iron, sodium, and preservatives [9] are in
the spotlight of research due to their possible negative effects on health. It is well known that high
meat intake, specifically red and processed meat, are associated with higher prevalence of metabolic
syndrome, impaired insulin sensitivity, type 2 diabetes, and oxidative stress [5,9,26]. Iron is present in
foods as heme or non-heme iron. Heme-iron is found mainly in animal based foods, and the rest of the
iron (animal or plant food) is non-heme iron [27]. Research studies have shown that meat or heme-iron
intake is related to serum ferritin concentration, and ferritin levels have been associated with glucose
and lipid profile alterations [15,27].
Excess circulating iron is potentially toxic, leading to the formation of reactive oxygen species,
which can contribute to oxidative stress in NASH [28,29]. Increased serum ferritin level is closely related
with insulin resistance and impaired glucose tolerance and NAFLD pathogenesis [30]. According to
Willman et al., 2019, after a 6-month dietary intervention, a significant decrease on ferritin levels
was found in participants corresponding to the “no red meat group” [31]. The reduction of ferritin
levels was positively correlated with liver fat content improvement. Our results corroborate that
meat consumption, specifically red meat, was associated with ferritin concentration which could be
influencing the development of NAFLD. Other research studies observed a relationship between ferritin
and elevated ALT, a surrogate of liver damage [30,32,33]. In this context, we observed that participants
above the median of red meat consumption presented higher ferritin and ALT concentrations than
those with lower red meat consumption.
Interestingly, a negative association between fish intake and ferritin concentration was observed in
the present study. The underlying mechanism responsible for this relation cannot be clarified, however,
it could be hypothesized that fish composition, mainly fatty fish, characterized by their Omega-3 PUFAs
content, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) might exert beneficial
effects on ferritin levels. Several studies have shown that omega-3 PUFAs are inversely associated
with NAFLD, by decreasing proinflammatory molecules, serum triglycerides, and improving liver
histology [10,34].
Ferritin is a protein implicated in iron metabolism and reflects the iron storage of the organism.
However, in inflammatory conditions ferritin concentrations are increased and it is synthesized as an
acute phase protein, acting as a pro-inflammatory molecule capable of inducing liver damage. [33,35–37].
The potential anti-inflammatory effect and antioxidant capacity of omega-3 PUFAs [38], might
ameliorate ferritin pro-oxidant and pro-inflammatory activity, although the exact molecular pathways
are yet to be elucidated.
The liver is the principal iron-storage organ and plays a central role in iron metabolism [4,35].
Increased hepatic iron concentrations are associated with metabolic alterations including insulin
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resistance and type 2 diabetes [15]. This condition is commonly known as dysmetabolic iron overload
syndrome (DIOS) [15,39,40]. Mild-to-moderate hepatic iron accumulation is identified in NAFLD and
other liver diseases. It has been suggested that one third of patients with NAFLD have DIOS [15,37].
Recent studies have shown that higher liver iron content is associated with the progression of NAFLD,
including development of steatohepatitis, advanced fibrosis, and cirrhosis [15,41].
Magnetic resonance imaging is an emerging and non-invasive method for assessing liver iron
and hepatic steatosis [6,15,39]. Our findings suggest that red and processed meat are partly associated
with liver iron content. Quantile regression analyses corroborated the positive association between
processed meat consumption and liver iron accumulation and the negative association between fish
intake and ferritin concentration. McKay et al., 2018 reported a positive association between beef
consumption and liver iron content assessed by MRI in a study population over than 9000 subjects [15].
Interestingly, other authors have described that iron absorption is increased in some patients with
NAFLD, due to the overexpression of the divalent metal transporter 1 (DMT1) [29]. Due to the high
bioavailability, heme-iron absorption rates are four to five times higher than non-heme iron, considered
as the main contributor to stored body iron [42]. The detrimental effects of liver iron and ferritin on
health have been described by several authors [29,30,42].
Contrary to our expectations, subjects with higher processed meat consumption registered lower
liver stiffness values, while previous studies indicated that processed meat consumption was associated
with an increased risk of chronic liver disease [43]. This result might be explained since transient
elastography is a technique to assess the presence of advanced fibrosis or cirrhosis [44] and according to
several authors, the cut-off point in order to determine liver fibrosis ranges from 6.5 to 8 kPa [6,45–47].
Our study population presented lower liver stiffness values, suggesting that participants did not
present hepatic fibrosis. In this sense, it can be hypothesized that the infiltration of lipid droplets in the
hepatocytes might promote structural changes in the liver, altering hepatic elasticity and disrupting
the wave propagation through the liver registering contradictory results. Likewise, the interpretation
of elastography results must be evaluated with caution to establish any possible association between
liver stiffness and processed meat consumption. Potential limitations have been described for the
use of transient elastography in NAFLD, related to the high failure due to invalid measurements in
patients with high BMI and/or central obesity [28,46].
It is important to mention some limitations of the present study: firstly, other components of
animal protein sources (such as vitamins) and cooking methods might also influence the observed
results. Secondly, dietary data were collected by using self-reported information of the participants,
and thus, our results are susceptible to some degree of bias. Thirdly, causal inference cannot be made
due to the cross-sectional design of this investigation. On the other hand, some strengths can be
mentioned as well, such as participants were carefully selected following exclusion and inclusion
criteria to avoid a heterogeneous sample. Participants were well characterized and the methodology
used to assess liver status was ultrasonography, ARFI, and MRI (a robust and accurate method to
determine iron and fat concentration in liver) and to our knowledge, few studies have evaluated the
association of different animal protein source consumption in subjects with NAFLD.
5. Conclusions
Processed meat consumption might influence hepatic iron concentration, while fish intake
improved ferritin levels, both proposed as potential risk factors in the development and progression of
NAFLD. These findings suggest that the consumption of different animal protein sources differentially
impact on liver status of obese subjects with NAFLD.
Author Contributions: Conceptualization, G.R., B.A.M.-A., I.C., J.I.M., J.I.H., A.B.-B., M.E., J.A.T., J.A.M., M.A.Z.
and I.A.; Data curation, G.R., B.A.M.-A., J.A.M., M.A.Z. and I.A.; Formal analysis, G.R., J.A.M., M.A.Z. and I.A.;
Funding acquisition, J.A.T., J.A.M. and M.A.Z.; Investigation, G.R., J.A.M., M.A.Z. and I.A.; Methodology, G.R.,
B.A.M.-A., I.C., J.I.M., J.I.H., A.B.-B., M.E., J.A.M., M.A.Z. and I.A.; Project administration, J.A.T., J.A.M., M.A.Z.
and I.A.; Resources, G.R., B.A.M.-A., J.A.M., M.A.Z. and I.A.; Validation, G.R., B.A.M.-A., J.A.M., M.A.Z. and I.A.;
Nutrients 2019, 11, 2359 9 of 11
Visualization, G.R., M.A.Z. and I.A.; Writing—original draft, G.R., J.A.M., M.A.Z. and I.A.; Writing—review and
editing, G.R., J.A.M., M.A.Z. and I.A.
Funding: The FLiO study was funded by the Health Department of the Government of Navarra (61/2015),
CIBERobn (Physiopathology of Obesity and Nutrition) (CB12/03/3002) and Fundació La Marató de TV3 (201630.10).
Acknowledgments: The authors are especially grateful to all the participants of the FLiO study. All the authors
would like to thank the Government of Navarra, CIBERobn and Fundació La Marató de TV3 for the financial
support. Special thanks to the professional staff of the FLiO study for their contribution: Carmen Fuertes-Ran,
Verónica Ciaurriz, Vanessa Bullon-Vela, Cristina Galarregui, Alvaro San Juan-Rodriguez and to the nurses from
the departments of Clinical Chemistry, Radiology, Internal Medicine and the Liver Unit of the Clinica Universidad
de Navarra.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Tenorio-Jiménez, C.; Martínez-Ramírez, M.J.; Tercero-Lozano, M.; Arraiza-Irigoyen, C.; Del Castillo-Codes, I.;
Olza, J.; Plaza-Díaz, J.; Fontana, L.; Migueles, J.H.; Olivares, M.; et al. Evaluation of the effect of Lactobacillus
reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with
metabolic syndrome: A randomized clinical trial (PROSIR). BMC Complement. Altern. Med. 2018, 18, 1–8.
[CrossRef] [PubMed]
2. Vallianou, N.; Stratigou, T.; Christodoulatos, G.S.; Dalamaga, M. Understanding the Role of the Gut
Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current
Evidence and Perspectives. Curr. Obes. Rep. 2019, 8, 1–16. [CrossRef] [PubMed]
3. Cantero, I.; Abete, I.; Del Bas, J.M.; Caimari, A.; Arola, L.; Zulet, M.A.; Martinez, J.A. Changes in
lysophospholipids and liver status after weight loss: The RESMENA study. Nutr. Metab. 2018, 15,
1–11. [CrossRef]
4. Bessone, F.; Razori, M.V.; Roma, M.G. Molecular pathways of nonalcoholic fatty liver disease development
and progression. Cell. Mol. Life Sci. 2019, 76, 99–128. [CrossRef] [PubMed]
5. Perdomo, C.M.; Frühbeck, G.; Escalada, J. Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease.
Nutrients 2019, 11, 677. [CrossRef]
6. Cantero, I.; Elorz, M.; Abete, I.; Marin, B.A.; Herrero, J.I.; Monreal, J.I.; Benito, A.; Quiroga, J.; Martínez, A.;
Huarte, M.P.; et al. Ultrasound/elastography techniques, lipidomic and blood markers compared to magnetic
resonance imaging in non-alcoholic fatty liver disease adults. Int. J. Med. Sci. 2019, 16, 75–83. [CrossRef]
[PubMed]
7. Svegliati-Baroni, G.; Pierantonelli, I.; Torquato, P.; Marinelli, R.; Ferreri, C.; Chatgilialoglu, C.; Bartolini, D.;
Galli, F. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic.
Biol. Med. 2019, 1–16. [CrossRef]
8. Marin-Alejandre, B.A.; Abete, I.; Cantero, I.; Riezu-Boj, J.I.; Milagro, F.I.; Monreal, J.I.; Elorz, M.; Herrero, J.I.;
Benito-Boillos, A.; Quiroga, J.; et al. Association between sleep disturbances and liver status in obese subjects
with nonalcoholic fatty liver disease: A comparison with healthy controls. Nutrients 2019, 11, 322. [CrossRef]
9. Zelber-Sagi, S.; Ivancovsky-Wajcman, D.; Fliss, N.; Orenstein, D.; Shibolet, O.; Kariv, R. High red and
processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance.
J. Hepatol. 2018, 68, 1239–1246. [CrossRef]
10. Liu, X.; Peng, Y.; Chen, S.; Sun, Q. An observational study on the association between major dietary patterns
and non-alcoholic fatty liver disease in Chinese adolescents. Medicine 2018, 97, 1–7. [CrossRef]
11. Soleimani, D.; Rezvani, R.; Goshayeshi, L.; Nematy, M. Dietary patterns in relation to hepatic fibrosis among
patients with nonalcoholic fatty liver disease. Diabetes Metab. Syndr. Obes. Targets Ther. 2019, 12, 315–324.
[CrossRef]
12. Shi, L.; Brunius, C.; Johansson, I.; Bergdahl, I.A.; Lindahl, B.; Hanhineva, K.; Landberg, R. Plasma metabolites
associated with healthy Nordic dietary indexes and risk of type 2 diabetes—A nested case-control study in a
Swedish population. Am. J. Clin. Nutr. 2018, 108, 564–575. [CrossRef] [PubMed]
13. Luan, D.; Wang, D.; Campos, H.; Baylin, A. Red meat consumption and metabolic syndrome in the Costa
Rica Heart Study. Eur. J. Nutr. 2019, 1–9. [CrossRef] [PubMed]
14. Kim, Y.; Je, Y. Meat consumption and risk of metabolic syndrome: Results from the Korean population and a
meta-analysis of observational studies. Nutrients 2018, 10, 390. [CrossRef] [PubMed]
Nutrients 2019, 11, 2359 10 of 11
15. McKay, A.; Wilman, H.R.; Dennis, A.; Kelly, M.; Gyngell, M.L.; Neubauer, S.; Bell, J.D.; Banerjee, R.;
Thomas, E.L. Measurement of liver iron by magnetic resonance imaging in the UK Biobank population.
PLoS ONE 2018, 13, e0209340. [CrossRef] [PubMed]
16. Arendt, B.M.; Teterina, A.; Pettinelli, P.; Comelli, E.M.; Ma, D.W.L.; Fung, S.K.; McGilvray, I.D.; Fischer, S.E.;
Allard, J.P. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors
in non-alcoholic fatty liver disease. Nutrition 2019, 62, 100–107. [CrossRef]
17. De La Iglesia, R.; Lopez-Legarrea, P.; Abete, I.; Bondia-Pons, I.; Navas-Carretero, S.; Forga, L.; Martinez, J.A.;
Zulet, M.A. A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the
American heart association (AHA) guidelines: The MEtabolic Syndrome REduction in NAvarra (RESMENA)
project. Br. J. Nutr. 2014, 111, 643–652. [CrossRef]
18. Fernández-Ballart, J.D.; Piñol, J.L.; Zazpe, I.; Corella, D.; Carrasco, P.; Toledo, E.; Perez-Bauer, M.;
Martínez-González, M.Á.; Salas-Salvadó, J.; Martn-Moreno, J.M. Relative validity of a semi-quantitative
food-frequency questionnaire in an elderly Mediterranean population of Spain. Br. J. Nutr. 2010, 103,
1808–1816. [CrossRef]
19. Moreiras, O.; Carvajal, A.; Cabrera, L. Tablas de Composición de Alimentos Españoles (Spanish Food Composition
Tables); Pirámide: Madrid, Spain, 2009.
20. Wang, D.; Campos, H.; Baylin, A. Red meat intake is positively associated with non-fatal acute myocardial
infarction in the Costa Rica Heart Study. Br. J. Nutr. 2017, 118, 303–311. [CrossRef]
21. Colom, A.; Fiol, M.; Ruiz, M.; Compa, M.; Morey, M.; Moñino, M.; Romaguera, D. Association between
access to public open spaces and physical activity in a mediterranean population at high cardiovascular risk.
Int. J. Environ. Res. Public Health 2018, 15, 1285. [CrossRef]
22. Cassinotto, C.; Boursier, J.; de Lédinghen, V.; Lebigot, J.; Lapuyade, B.; Cales, P.; Hiriart, J.B.; Michalak, S.;
Bail, B.L.; Cartier, V.; et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic
shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology 2016, 63, 1817–1827. [CrossRef] [PubMed]
23. Zelber-Sagi, S.; Salomone, F.; Mlynarsky, L. The Mediterranean dietary pattern as the diet of choice for
non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017, 37, 936–949. [CrossRef]
[PubMed]
24. Fakhoury-Sayegh, N.; Younes, H.; Heraoui, G.N.H.A.; Sayegh, R. Nutritional profile and dietary patterns of
lebanese non-alcoholic fatty liver disease patients: A case-control study. Nutrients 2017, 9, 1245. [CrossRef]
[PubMed]
25. Kim, S.R.; Kim, K.; Lee, S.A.; Kwon, S.O.; Lee, J.K.; Keum, N.; Park, S.M. Effect of red, processed, and white
meat consumption on the risk of gastric cancer: An overall and dose-response meta-analysis. Nutrients 2019,
11, 826. [CrossRef]
26. Alshahrani, S.M.; Fraser, G.E.; Sabaté, J.; Knutsen, R.; Shavlik, D.; Mashchak, A.; Lloren, J.I.; Orlich, M.J.
Red and processed meat and mortality in a low meat intake population. Nutrients 2019, 11, 622. [CrossRef]
[PubMed]
27. Zhu, Z.; Wu, F.; Lu, Y.; Wu, C.; Wang, Z.; Zang, J.; Guo, C.; Jia, X.; Yao, J.; Peng, H.; et al. Total and nonheme
dietary iron intake is associated with metabolic syndrome and its components in Chinese men and women.
Nutrients 2018, 10, 1663. [CrossRef] [PubMed]
28. Zhou, J.H.; She, Z.G.; Li, H.L.; Cai, J.J. Noninvasive evaluation of nonalcoholic fatty liver disease: Current
evidence and practice. World J. Gastroenterol. 2019, 25, 1307–1326. [CrossRef]
29. Miyanishi, K.; Tanaka, S.; Sakamoto, H.; Kato, J. The role of iron in hepatic inflammation and hepatocellular
carcinoma. Free Radic. Biol. Med. 2019, 133, 200–205. [CrossRef]
30. Jung, J.Y.; Shim, J.J.; Park, S.K.; Ryoo, J.H.; Choi, J.M.; Oh, I.H.; Jung, K.W.; Cho, H.; Ki, M.; Won, Y.J.; et al.
Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol. Int.
2019, 13, 222–233. [CrossRef]
31. Willmann, C.; Heni, M.; Linder, K.; Wagner, R.; Stefan, N.; Machann, J.; Schulze, M.B.; Joost, H.G.; Häring, H.U.;
Fritsche, A. Potential effects of reduced red meat compared with increased fiber intake on glucose metabolism
and liver fat content: A randomized and controlled dietary intervention study. Am. J. Clin. Nutr. 2019, 109,
288–296. [CrossRef]
32. El Nakeeb, N.; Saleh, S.A.; Massoud, Y.M.; Hussein, A.; Hamed, R. Serum ferritin as a non-invasive marker in
the prediction of hepatic fibrosis among Egyptian patients with non-alcoholic fatty liver disease. JGH Open
2017, 1, 112–119. [CrossRef] [PubMed]
Nutrients 2019, 11, 2359 11 of 11
33. Shah, R.A.; Kowdley, K.V. Serum ferritin as a biomarker for NAFLD: Ready for prime time? Hepatol. Int.
2019, 13, 110–112. [CrossRef] [PubMed]
34. Nogueira, M.A.; Oliveira, C.P.; Ferreira Alves, V.A.; Stefano, J.T.; dos Reis Rodrigues, L.S.; Torrinhas, R.S.;
Cogliati, B.; Barbeiro, H.; Carrilho, F.J.; Waitzberg, D.L. Omega-3 polyunsaturated fatty acids in treating
non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2016, 35,
578–586. [CrossRef] [PubMed]
35. Pan, X.; Chen, B.; Liu, W.; Li, Y.; Hu, Z.; Lin, X.; Xu, S.; Peng, X.E. Circulating Iron Levels Interaction with
Central Obesity on the Risk of Nonalcoholic Fatty Liver Disease: A Case-Control Study in Southeast China.
Ann. Nutr. Metab. 2019, 74, 207–214. [CrossRef]
36. Modares Mousavi, S.R.; Geramizadeh, B.; Anushiravani, A.; Ejtehadi, F.; Anbardar, M.H.; Moini, M.
Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty
Liver Disease. Middle East J. Dig. Dis. 2018, 10, 90–95. [CrossRef] [PubMed]
37. Buzzetti, E.; Petta, S.; Manuguerra, R.; Luong, T.V.; Cabibi, D.; Corradini, E.; Craxì, A.; Pinzani, M.;
Tsochatzis, E.; Pietrangelo, A. Evaluating the association of serum ferritin and hepatic iron with disease
severity in non-alcoholic fatty liver disease. Liver Int. 2019, 39, 1325–1334. [CrossRef]
38. Tutino, V.; De Nunzio, V.; Caruso, M.G.; Bonfiglio, C.; Franco, I.; Mirizzi, A.; De Leonardis, G.; Cozzolongo, R.;
Giannuzzi, V.; Giannelli, G.; et al. Aerobic physical activity and a low glycemic diet reduce the AA/EPA ratio
in red blood cell membranes of patients with NAFLD. Nutrients 2018, 10, 1299. [CrossRef] [PubMed]
39. Ryan, J.D.; Armitage, A.E.; Cobbold, J.F.; Banerjee, R.; Borsani, O.; Dongiovanni, P.; Neubauer, S.; Morovat, R.;
Wang, L.M.; Pasricha, S.R.; et al. Hepatic iron is the major determinant of serum ferritin in NAFLD patients.
Liver Int. 2018, 38, 164–173. [CrossRef]
40. Sabrina, N.; Bai, C.H.; Chang, C.C.; Chien, Y.W.; Chen, J.R.; Chang, J.S. Serum iron:Ferritin ratio predicts
healthy body composition and reduced risk of severe fatty liver in young adult women. Nutrients 2017, 9,
833. [CrossRef]
41. Britton, L.; Bridle, K.; Reiling, J.; Santrampurwala, N.; Wockner, L.; Ching, H.; Stuart, K.; Subramaniam, V.N.;
Jeffrey, G.; St. Pierre, T.; et al. Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic
fatty liver disease. Hepatol. Commun. 2018, 2, 644–653. [CrossRef]
42. Peng, X.E.; Xu, S.H.; Liu, W.; Hu, Z.; Lin, Z.; Lin, X. Independent and combined effects of dietary iron
composition and selected risk factors on the risk of NAFLD in a Chinese population. Sci. Rep. 2019, 9, 1–8.
[CrossRef] [PubMed]
43. Freedman, N.D.; Cross, A.J.; McGlynn, K.A.; Abnet, C.C.; Park, Y.; Hollenbeck, A.R.; Schatzkin, A.;
Everhart, J.E.; Sinha, R. Association of meat and fat intake with liver disease and hepatocellular carcinoma in
the NIH-AARP cohort. J. Natl. Cancer Inst. 2010, 102, 1354–1365. [CrossRef] [PubMed]
44. Wong, V.W.S.; Adams, L.A.; de Lédinghen, V.; Wong, G.L.H.; Sookoian, S. Noninvasive biomarkers in NAFLD
and NASH—Current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 461–478.
[CrossRef] [PubMed]
45. Katsagoni, C.N.; Papatheodoridis, G.V.; Ioannidou, P.; Deutsch, M.; Alexopoulou, A.; Papadopoulos, N.;
Papageorgiou, M.V.; Fragopoulou, E.; Kontogianni, M.D. Improvements in clinical characteristics of patients
with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: A randomised
controlled clinical trial. Br. J. Nutr. 2018, 120, 164–175. [CrossRef] [PubMed]
46. Stål, P. Liver fibrosis in non-alcoholic fatty liver disease—Diagnostic challenge with prognostic significance.
World J. Gastroenterol. 2015, 21, 11077–11087. [CrossRef] [PubMed]
47. Alferink, L.J.M.; Trajanoska, K.; Erler, N.S.; Schoufour, J.D.; Knegt, R.J.; Ikram, M.A.; Janssen, H.L.A.;
Franco, O.H.; Metselaar, H.J.; Rivadeneira, F.; et al. Nonalcoholic Fatty Liver Disease in The Rotterdam Study:
About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. J. Bone Miner. Res. 2019, 1–10. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
